PIRS - Pieris spikes 11% on data for gastric cancer candidate

2023-04-17 14:33:27 ET

• Pieris Pharmaceuticals ( NASDAQ: PIRS ) added ~11% on Monday after announcing the latest data for its investigational bispecific cinrebafusp alfa from a mid-stage trial for patients with HER2-positive gastric cancer at the ongoing annual meeting of the American Association for Cancer Research.
• Boston, Massachusetts-based Pieris ( PIRS ) said that cinrebafusp alfa, also known as PRS-343, led to a partial clinical response in all patients in the open-label Phase 2 study as of December 19, 2022, data cutoff.
• The patients in the study had previously received trastuzumab, and a checkpoint blockade, while three had previously received and progressed on-trastuzumab deruxtecan.
• Pieris ( PIRS ) is currently weighing a range of transactions to support future studies for cinrebafusp alfa after discontinuing the Phase 2 trial in August due to strategic reasons.

For further details see: